# Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

> **NCT00374933** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 18 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI
- **DRUG:** "Prophylactic" delayed ADLI
- **DRUG:** "Prophylactic" delayed activated donor lymphocyte infusion

## Key facts

- **NCT ID:** NCT00374933
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00374933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00374933, "Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00374933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*